PPCB Propanc Biopharma Inc

A clinical start date is one milestone. The work required to reach it happens long before. At $PPCB, GMP manufacturing is underway, raw drug substance supply is secured, PK method validation has commenced, and regulatory documentation is advancing toward the planned November HREC submission. Across biotech, companies such as $RCKT in rare cardiovascular disease and $DTIL in Duchenne muscular dystrophy are advancing through their own clinical development paths. Different diseases require different science, but execution is what moves programs forward. For PRP, that work is advancing today toward the targeted February 2027 Phase 1b First-In-Human study. Each milestone brings PRP one step closer to clinical evaluation.

$PPCB highlighted preclinical data showing PRP reprograms chemo-resistant pancreatic cancer cells, paving way for a Phase 1b trial.

$PPCB Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer

PRP’s path to the clinic is no longer just a development plan. The infrastructure behind it is taking shape. $PPCB has established key relationships supporting Phase 1b, including Avance Clinical for clinical delivery, a specialized CDMO for GMP manufacturing, and FyoniBio for PRP’s PK assay. Clinical development requires multiple pieces to come together. For PRP, those pieces are now being put in place. The foundation for the next stage is being built now. $IONS $BEAM

$PPCB is advancing multiple workstreams in parallel to support PRP’s move into the clinic. GMP manufacturing is underway. Raw drug substance supply is secured. PK method validation has commenced. Regulatory documentation is being prepared ahead of the planned November HREC submission. Across biotech, different technologies are following their own paths toward patients—from mRNA-based medicines at $MRNA to gene-editing approaches at $CRSP. For PRP, the work behind Phase 1b is already underway.

$PPCB Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

$PPCB Dumpster fire :)) Their AI just said : "During FY2026, $PPCB raised $7.5M in gross proceeds. Since June 30, the Company has received an additional $2M through its Series C facility, which the Company expects to support planned R&D activities," From WHO's money? From dilution since they have zero revenue. Dilution = they sell some paper [promises] to you and then take THE SAME paper and sell it to somebody else also. | Claiming that: don't worry, all of you are lucky! :)) And it's not even actually "TRUE", it's fraud. It's like this: FORM 10-K | For the fiscal year ended June 30, 2026 "Repurchase Plan Between July 2026 and August 2026, the Company repurchased 320,031 shares of its common stock under the Repurchase Plan for an aggregate purchase price of approximately $500,000, at an average purchase price of $1.56 per share." next paragraph: "Shares issued for services On July 24, 2026, the Company issued an aggregate of 3,500,000 shares of common stock to (..) directors (..).

$PPCB low float Float: ~1.27M – 2.04M sharesShares Outstanding: ~2.28M sharesHeld by Insiders: ~46.47%Held by Institutions: ~1.37%

$PPCB Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 GLOBENEWSWIRE 7:30 AM ET 9/22/2026 New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset

$PPCB 1576 watchers all got taken to the cleaners by this stock. When is the next reverse split. Where is the stock buyback. One of these two things will happen. One won't. Which will it be? I will start. Reverse split.

$PPCB Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells

$PPCB new 52 week low on PR 😂 for such a low float stock. The people are seeing through the fraud……

$PPCB Don't be caught after the 15th October pump since their purpose is to actually dump them [not yet capable] + remain above $1 for at least 10 day after the split (they will crash it again in January with the lie of February badabum but now we know that "First Patient - April 2027", same LIE we get since 2015 month-after-month year-after-year). The split will attract the activity though don't forget that your amount of shares is also thrown in the gutters, imagine if they do 100:1, now you say: yay I got 10 shares in this $1.5 move ...from your initial 1000 =)) Best would be to short it in mass to not allow it to go too high so they can't instantly dump them and prolong some pain, some undercover manipulative rebuy from them. Whatever you see on the tape do no believe it's short, not everything is short as some old comments below claimed. You wait for a squeeze and what do you get at that level? Suurpriiise! 1,2,4 tops, you know them :)) 15th Oct. mark my prediction, let's see :D :))

$PPCB Stop wasting time with useless news updates. When are you actually going to stop dumping your shares? PPCB is the absolute worst-performing stock out of the 5,000 I watch .. your handling of this company is a complete joke !

$PPCB low float……but damn, this has been a non stop nose dive. Would love to see some meaningful PR and this thing can launch 200% quickly.

$PPCB There are bad stocks, there are total scams, and then there is a 99% dilution death spiral such as this pos

$PPCB From $4 to $0.30 with barely a relief bounce—an absolutely brutal collapse. Of the 4,000–5,000 stocks I’ve watched over the past six months, this is the worst price action I’ve seen. In my opinion, it’s not worth a single dollar. Just stay away

$PPCB This is a $20 stock soon Data Showing Over 90% Tumor Growth Inhibition Repurchase $5 million of shares Mcap only $4 million

$PPCB Propanc Biopharma Says Published Pilot Study Showed 85.9% Mean Tumor Weight Reduction With PRP In Pancreatic Cancer Animal Model BENZINGA 7:32 AM ET 10/14/2026

$PPCB I am optimistic about the stock, but it just seems right now that they are recycling the same press release by comparing the same findings with a different product each week or every two weeks. I suppose to allow for a weekly press release and create the appearance that things are active and they are being diligent and proactive about keeping shareholders informed.